Psychotropic drugs can penetrate the blood–brain barrier and regulate the levels of
neurotransmitters and neuromodulators such as γ-aminobutyric acid, glutamate, serotonin …

Glioblastoma multiforme (GBM) is the most malignant primary adult brain tumor. The current
standard of care is surgical resection, radiation, and chemotherapy treatment, which extends …

Glioblastoma (GBM) is associated with a very dismal prognosis, and current therapeutic
options still retain an overall unsatisfactorily efficacy in clinical practice. Therefore, novel …

Glioblastoma multiforme (GBM) is the most common and most lethal primary brain tumor,
with tragically little therapeutic progress over the last 30 years. Surgery provides a modest …

Despite numerous advancements in the last decade, human gliomas such as astrocytoma
and glioblastoma multiforme have the worst prognoses among all cancers. Anti-psychotic …

Cancer is a major public health problem and one of the leading contributors to the global
disease burden. The high cost of development of new drugs and the increasingly severe …

Glioblastoma is a brain neoplasm with limited 5‐year survival rates. Developments of new
treatment regimens that improve patient survival in patients with glioblastoma are needed. It …

This article demonstrates that drug delivery to brain tumors is a function of both drug
properties and tumor properties and that both must be considered in planning …

Abstract The North American Brain Tumor Consortium (NABTC) is a multi-institutional
consortium with the primary objective of evaluating novel therapeutic strategies through …

Traditionally, the majority of phase I studies of novel agents in oncology have excluded
patients with primary brain tumors. Although phase I studies are designed to determine …